No stone unturned in UK PPRS negotiations
This article was originally published in Scrip
Executive Summary
The UK department of healthis leaving no stone unturned during its negotiations on a new pharmaceutical price regulation scheme. It has written to NHS Trusts to gather information on medicines dispensed at home although prescribed in secondary care (hospitals). These products may have bypassed the pharmacy information systems which are being used to collect information on drug prescribing in hospitals. The growth of medicines expenditure in secondary care is significantly higher than in community care, the department points out. It also notes that the headline agreement with the industry signed in June called for a price cut of 2% for medicines if the actual rate of growth in the drugs bill in primary and secondary care in England exceeds 6.7% in either 2008 or in 2009. As the NHS branded drugs bill in primary and secondary care currently stands at £8 billion, the savings the government would get if this additional 2% is triggered would be substantial, the DoH comments.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.